Literature DB >> 11466330

CD1d-restricted NKT cells: an interstrain comparison.

K J Hammond1, D G Pellicci, L D Poulton, O V Naidenko, A A Scalzo, A G Baxter, D I Godfrey.   

Abstract

CD1d-restricted Valpha14-Jalpha281 invariant alphabetaTCR(+) (NKT) cells are well defined in the C57BL/6 mouse strain, but they remain poorly characterized in non-NK1.1-expressing strains. Surrogate markers for NKT cells such as alphabetaTCR(+)CD4(-)CD8(-) and DX5(+)CD3(+) have been used in many studies, although their effectiveness in defining this lineage remains to be verified. Here, we compare NKT cells among C57BL/6, NK1.1-congenic BALB/c, and NK1.1-congenic nonobese diabetic mice. NKT cells were identified and compared using a range of approaches: NK1.1 expression, surrogate phenotypes used in previous studies, labeling with CD1d/alpha-galactosylceramide tetramers, and cytokine production. Our results demonstrate that NKT cells and their CD4/CD8-defined subsets are present in all three strains, and confirm that nonobese diabetic mice have a numerical and functional deficiency in these cells. We also highlight the hazards of using surrogate phenotypes, none of which accurately identify NKT cells, and one in particular (DX5(+)CD3(+)) actually excludes these cells. Finally, our results support the concept that NK1.1 expression may not be an ideal marker for CD1d-restricted NKT cells, many of which are NK1.1-negative, especially within the CD4(+) subset and particularly in NK1.1-congenic BALB/c mice.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11466330     DOI: 10.4049/jimmunol.167.3.1164

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  71 in total

1.  Slam haplotypes modulate the response to lipopolysaccharide in vivo through control of NKT cell number and function.

Authors:  Idil Aktan; Alan Chant; Zachary D Borg; David E Damby; Paige C Leenstra; Graham W J Lilley; Graham W G Lilley; Joseph Petty; Benjamin T Suratt; Cory Teuscher; Edward K Wakeland; Matthew E Poynter; Jonathan E Boyson
Journal:  J Immunol       Date:  2010-06-07       Impact factor: 5.422

Review 2.  Regulation of immune responses by CD1d-restricted natural killer T cells.

Authors:  Luc Van Kaer
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

Review 3.  Going both ways: immune regulation via CD1d-dependent NKT cells.

Authors:  Dale I Godfrey; Mitchell Kronenberg
Journal:  J Clin Invest       Date:  2004-11       Impact factor: 14.808

Review 4.  Alternative memory in the CD8 T cell lineage.

Authors:  You Jeong Lee; Stephen C Jameson; Kristin A Hogquist
Journal:  Trends Immunol       Date:  2011-02-01       Impact factor: 16.687

5.  Type 1 diabetes and NKT cells: a report on the 3rd International Workshop on NKT cells and CD1-mediated antigen presentation, September 2004, Heron Island, QLD, Australia.

Authors:  Julie M Fletcher; Margaret A Jordan; Alan G Baxter
Journal:  Rev Diabet Stud       Date:  2004-11-10

Review 6.  NKT cells at the maternal-fetal interface.

Authors:  J E Boyson; I Aktan; D A Barkhuff; A Chant
Journal:  Immunol Invest       Date:  2008       Impact factor: 3.657

Review 7.  Biological implications of extracellular adenosine in hepatic ischemia and reperfusion injury.

Authors:  M A Zimmerman; I Kam; H Eltzschig; A Grenz
Journal:  Am J Transplant       Date:  2013-08-07       Impact factor: 8.086

8.  The transcription factor Th-POK negatively regulates Th17 differentiation in Vα14i NKT cells.

Authors:  Isaac Engel; Meng Zhao; Dietmar Kappes; Ichiro Taniuchi; Mitchell Kronenberg
Journal:  Blood       Date:  2012-10-03       Impact factor: 22.113

Review 9.  Overview of a HLA-Ig based "Lego-like system" for T cell monitoring, modulation and expansion.

Authors:  Mathias Oelke; Jonathan P Schneck
Journal:  Immunol Res       Date:  2010-07       Impact factor: 2.829

10.  Aberrant endometrial features of pregnancy in diabetic NOD mice.

Authors:  Suzanne D Burke; Hongmei Dong; Aleah D Hazan; B Anne Croy
Journal:  Diabetes       Date:  2007-09-07       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.